Verastem (NASDAQ:VSTM) Given Buy Rating at BTIG Research

BTIG Research restated their buy rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a research report released on Tuesday morning,Benzinga reports. BTIG Research currently has a $20.00 price objective on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on the company. Wall Street Zen upgraded Verastem from […]

Leave a Reply

Your email address will not be published.

Previous post Metsera (NASDAQ:MTSR) Coverage Initiated at Leerink Partners
Next post Alkermes’ (ALKS) “Neutral” Rating Reiterated at HC Wainwright